Note 1: This field and Site-Specific Factor 3, CS Extension - Pathologic Extension, must both be coded, whether or not a prostatectomy was performed.Information from prostatectomy is EXCLUDED from this field and coded only in Site-Specific Factor 3.
Note 3: Prostate Apex Involvement:This field and Site-Specific Factor 4, Prostate Apex Involvement, are both coded whether or not a prostatectomy was performed.
Note 4: Use codes 13-14 when a TURP is done, not for a biopsy only. Do not use code 15 when a TURP is done.
Note 5: Involvement of the prostatic urethra does not alter the extension code.
Note 6: "Frozen pelvis" is a clinical term which means tumor extends to pelvic sidewall(s).In the absence of a more detailed statement of involvement, assign this to code 60.
Note 7: AUA stage.Some of the American Urological Association (AUA) stages A-D are provided as guidelines for coding in the absence of more specific information in the medical record. If physician-assigned AUA stage D1-D2 is based on involvement of lymph nodes only, code under CS Lymph Nodes or CS Mets at DX, not CS Extension.
Note 8: This schema includes evaluation of other pathologic tissue such as a biopsy of the rectum.
Note 9: For the extension fields for this site, the mapping values for TNM, SS77, and SS2000 and the associated c, p, y, or a indicator are assigned based on the values in CS Extension, CS TS/Eval, and Site-Specific Factor 3.If the value of Site-Specific Factor 3: Pathologic Extension is greater than 000 and less than 095 (i.e., prostatectomy was done, extension information is available for staging, and invasive tumor was present in the prostatectomy specimen), the mapping values are taken from the Site-Specific Factor 3 mapping, and the T category is identified as a pT.If Site-Specific Factor 3: Pathologic Extension code is 95 or greater (meaning that prostatectomy was not performed, or it was performed but the information is not usable for staging), the mapping values are taken from the CS Extension (Clinical Extension) mapping, and the c, p, y, or a indicator is taken from the TS/Ext Eval mapping.If Site-Specific Factor 3: Pathologic Extension code is 000 (in situ), and if CS Extension code (Clincal Extension) is greater than 00 and less than 95 (not in situ) , the mapping values are taken from the CS Extension (Clinical Extension) mapping, and the c, p, y, or a indicator is taken from the TS/Ext Eval mapping. If Site-Specific Factor 3 code is 000 (in situ) and CS Extension code is 00 (in situ) or greater than 94, the mapping values are taken from the Site-Specific Factor 3 mapping, and the T category is identified as a pT.
|00||In situ: noninvasive; intraepithelial||Tis||IS||IS|
|10||Clinically inapparent tumor, number of foci or percent involved tissue not specified
Stage A, NOS
|13||Incidental histologic finding in 5% or less of tissue resected (clinically inapparent)||T1a||L||L|
|14||Incidental histologic finding more than 5% of tissue resected (clinically inapparent)||T1b||L||L|
|15||Tumor identified by needle biopsy, e.g., for elevated PSA (clinically inapparent)||T1c||L||L|
|20||Involvement in one lobe, NOS (clinically apparent only)||T2NOS||L||L|
|21||Involves one half of one lobe or less (clinically apparent only)||T2a||L||L|
|22||Involves more than one half of one lobe, but not both lobes (clinically apparent only)||T2b||L||L|
|23||Involves both lobes (clinically apparent only)||T2c||L||L|
|24||Clinically apparent tumor confined to prostate, NOS
Stage B, NOS
|31||OBSOLETE (See Notes 2, 3 and Site-Specific Factor 4)||T2NOS||L||L|
|33||OBSOLETE (See Notes 2, 3 and Site-Specific Factor 4)||T2NOS||L||L|
|34||OBSOLETE (See Notes 2, 3 and Site-Specific Factor 4)||T2NOS||L||L|
|42||Unilateral extracapsular extension||T3a||RE||RE|
|43||Bilateral extracapsular extension||T3a||RE||RE|
|45||Extension to seminal vesicle(s) (Stage C2)||T3b||RE||RE|
|49||Periprostatic extension, NOS (Unknown if seminal vesicle(s) involved)
Stage C, NOS
|50||Extension to or fixation to adjacent structures other than seminal vesicles:
|70||Further contiguous extension (Stage D2) including to:
|95||No evidence of primary tumor||T0||U||U|